Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
10. Januar 2025 07:30 ET
|
Absci Corporation; Owkin
VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock...
Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery
08. Januar 2025 07:00 ET
|
Absci Corporation
VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy...
Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health
06. Januar 2025 08:00 ET
|
Absci Corporation; Invetx
VANCOUVER, Wash. and BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Invetx, a pioneer in protein-based therapeutics...
Absci to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
02. Januar 2025 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating...
Absci Highlights Progress and Updates Across Proprietary Pipeline and Leading AI Platform at 2024 R&D Day
12. Dezember 2024 08:00 ET
|
Absci Corporation
Drug candidate selected for ABS-201, a novel, potentially category-defining anti-PRLR antibody in development for androgenic alopecia Leading AI platform demonstrated breakthrough in successful...
Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference
21. November 2024 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating...
Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results
12. November 2024 07:30 ET
|
Absci Corporation
Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration Entered into collaboration with Twist Bioscience to design a novel...
Absci to Host R&D Day on December 12, 2024
07. November 2024 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will host its 2024...
Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI
31. Oktober 2024 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI) a data-first generative AI drug creation company, and Twist Bioscience...
Absci to Participate in Upcoming Investor Conferences
24. Oktober 2024 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating...